Articles

Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study

Tianyi Wang, Mandy Che, Yash S. Huilgol, et al. NPJ Breast Cancer | (2024) 10:90

Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast health decision tool impacted a participant’s willingness to start risk-reducing act... Read More

24 Mar, 2026

Risk-Based vs Annual Breast Cancer Screening. The WISDOM Randomized Clinical Trial

Laura J. Esserman; Allison S. Fiscalini; Arash Naeim. JAMA Published online December 12, 2025

Individual breast cancer risk can guide screening initiation, frequency, use of supplemental imaging, and preventive measures to improve breast cancer screening by shifting resources from low-risk women to high-risk women. To determine whether risk-based breast cancer screening is a feasible alternative to annual mammo... Read More

24 Mar, 2026

Global patterns and trends in breast cancer incidence and mortality across 185 countries

Joanne Kim, Andrew Harper, Valerie McCormack, et al.  Nat Med. 2025 Apr;31(4):1154-1162.

Updates of current and projected estimates of the burden are critical to monitoring the success of ongoing efforts in breast cancer control, such as the World Health Organization Global Breast Cancer Initiative, which aims to reduce breast cancer mortality by 2.5% per year. We investigated the current (2022) and future... Read More

24 Mar, 2026

Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer

Xiang Li, Qiuyuan Li, Fujun Yang, et al. Ann Thorac Surg. 2025 Jun;119(6):1185-1195

This study was carried out to evaluate the impact of neoadjuvant therapy on long-term survival of patients with non-small cell lung cancer undergoing sleeve lobectomy. A total of 613 patients were retrospectively analyzed, including 124 who received neoadjuvant therapy. Neoadjuvant therapy was associated with improved ... Read More

24 Mar, 2026

Smoking Cessation Treatment Efficacy and Impact on Health Outcomes Among Middle-Aged and Older Adults: A Scoping Review

Adrienne L. Johnson, Jaqueline C. Avila, Leslie Christensen, et al. Nicotine and Tobacco Research, 2025, 00, 1–12

Middle-aged and older adults (aged ≥ 45 years) have historically been overlooked in tobacco research and policy despite a quit rate that is half of younger adults and the greatest near-term harms of tobacco use. A scoping review was conducted on smoking cessation treatment efficacy and its impact on health outcomes amo... Read More

24 Mar, 2026

Global advances and future directions in lung cancer care: expert consensus and strategic priorities

ML. Meyer, S. Peters, PA Jänne, TS Mok. Et al. ESMO Open. 2026 Feb;11(2):106034

Over the past decade, lung cancer management has been reshaped by advances in early detection, treatment, and prevention. Prevention now extends beyond tobacco control to include recognition of non-tobacco risk factors, screening, and incidental nodule programs. Yet progress in primary prevention remains uneven, with m... Read More

24 Mar, 2026

Disease burden of trachea, bronchus and lung cancer 1990-2021 and global trends projected to 2035

Xin Zhang, Jing Zou, Jinghua Ning,et al. Sci Rep. 2025 Feb 20;15(1):6264

Tracheal, bronchial, and lung cancer (TBL) is among the most common malignancies worldwide, with persistently high incidence and mortality rates, posing a significant threat to public health. This study comprehensively evaluated the global, regional, and national burden of TBL across 204 countries and territories from ... Read More

24 Mar, 2026

Global burden of lung cancer in 2022 and projected burden in 2050

Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Chinese Medical Journal 2024;137(21)

Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases and deaths due to lung cancer in China and the United States in 2050. Globally, an estima... Read More

24 Mar, 2026

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis

Yixin Zhou, Anlin Li, Hui Yu, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241285

Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates among patients with resectable non-small cell lung cancer (NSCLC). However, it remains controv... Read More

24 Mar, 2026

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708

In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, the estimated 12-month event-free survival was 83.7% in the neoadjuvant group... Read More

24 Mar, 2026